Aclarion (ACON) News Today $3.21 -0.05 (-1.53%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$3.18 -0.03 (-0.93%) As of 05/22/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock ACON Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2026 April 2026 March 2026 February 2026 January 2026 December 2025 November 2025 October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 Time Period Aclarion (ACON) Expected to Announce Quarterly Earnings on ThursdayMay 14, 2026 | americanbankingnews.comInsider Buying: Aclarion (NASDAQ:ACON) Director Buys 5,664 Shares of StockMay 13, 2026 | insidertrades.comAclarion (NASDAQ:ACON) CEO Brent Ness Acquires 6,289 SharesMay 12, 2026 | insidertrades.comAclarion Announces Addition of First Private Practice Site in Los Angeles into CLARITY Trial to Further Accelerate EnrollmentMay 7, 2026 | globenewswire.comAclarion Announces Inducement Grant to New Commercial Director, Western U.S.May 6, 2026 | globenewswire.comAclarion Announces Second Commercial Agreement with Weill Cornell MedicineMay 5, 2026 | globenewswire.comAclarion Delivers Strong Q1 2026 Results with 196% Annual Scan Volume Growth Reflecting Accelerating Clinical AdoptionApril 30, 2026 | globenewswire.comAclarion Appoints Daniel Keefe as Commercial Director, Western U.S., to Drive Continued Adoption of NociscanApril 28, 2026 | globenewswire.comAclarion Launches $2.5 Million Share Repurchase ProgramApril 22, 2026 | tipranks.comAclarion Announces $2.5 Million Stock Repurchase PlanApril 22, 2026 | globenewswire.comAclarion, Inc. Secures U.S. Patent for AI-Enhanced Machine Learning Platform in Chronic Low Back Pain DiagnosisApril 16, 2026 | quiverquant.comQAclarion Secures U.S. Patent Advancing Scalable, AI-Driven Assessment of Chronic Low Back PainApril 16, 2026 | globenewswire.comAclarion Receives Pinnacle Award for AI InnovationApril 14, 2026 | globenewswire.comAclarion (ACON) price target decreased by 69.57% to 7.14April 9, 2026 | msn.comAclarion Announces Agreement with Weill Cornell MedicineApril 8, 2026 | globenewswire.comAclarion Highlights Growing Adoption of Nociscan at The London Clinic with New Physician VideoApril 7, 2026 | globenewswire.comAclarion Adopts One-Year Stockholder Rights Protection PlanMarch 19, 2026 | tipranks.comAclarion, Inc. Adopts Limited Duration Stockholder Rights PlanMarch 19, 2026 | globenewswire.comAclarion, Inc. Pursues Insurance Reimbursement Initiatives and Reports Strong Momentum Leading into 2026March 19, 2026 | quiverquant.comQAclarion Publishes CEO Shareholder Letter Highlighting Strategic Progress and 2026 CatalystsMarch 19, 2026 | globenewswire.comAclarion, Inc. to Engage with Investors at the 38th Annual ROTH Conference Regarding Nociscan AdvancementsMarch 17, 2026 | quiverquant.comQAclarion to Participate in the 38th Annual ROTH Conference, Highlighting Key 2026 Catalysts and Strong Balance SheetMarch 17, 2026 | globenewswire.comAclarion, Inc. CEO Brent Ness to Attend LSI USA 2026 to Discuss NOCISCAN and Industry PartnershipsMarch 12, 2026 | quiverquant.comQAclarion CEO Brent Ness to Attend LSI USA 2026March 12, 2026 | globenewswire.comAclarion Publishes 2026 Shareholder Letter from the ChairmanFebruary 5, 2026 | globenewswire.comExclusive: Aclarion CEO looks to bigger AI MedTech’s playbook to reverse fortunesFebruary 4, 2026 | msn.comAclarion Adds High-Volume Practice, Source Healthcare, to Support Nociscan Growth and Real-World Evidence GenerationFebruary 3, 2026 | globenewswire.comAclarion Raises $10.4 Million, Sharpens Focus On Nociscan RolloutJanuary 13, 2026 | benzinga.comAclarion Strengthens Balance Sheet With New Equity FinancingJanuary 13, 2026 | tipranks.comAclarion, Inc. Secures $10.4 Million in Common-Stock Financing to Strengthen Balance Sheet and Extend Operating RunwayJanuary 13, 2026 | quiverquant.comQAclarion Strengthens Balance Sheet and Extends Cash Runway Into 2028January 13, 2026 | globenewswire.comAclarion shares surge after sharp rise in Q4 Nociscan usageJanuary 9, 2026 | msn.comAclarion stock soars on 114% jump in Q4 Nociscan scan volumesJanuary 8, 2026 | au.investing.comACON stock pops 45% pre-market today: What’s driving the move?January 8, 2026 | msn.comAclarion to enroll around 25% of patients in CLARITY trial by Q2January 8, 2026 | msn.comAclarion Reports 114% Year-Over-Year Increase in Nociscan Scan Volumes for Q4 2025 and Financial Strength with $12 Million Cash BalanceJanuary 8, 2026 | quiverquant.comQAclarion Provides 2025 Update and 2026 Corporate OutlookJanuary 8, 2026 | globenewswire.comAclarion Advances Patient Enrollment in CLARITY Trial with Northwestern Medicine and Scripps Health ParticipationJanuary 6, 2026 | quiverquant.comQAclarion Announces First Patient Enrollments at Two Additional CLARITY Trial Sites and Provides Guidance on Expected Availability of Initial DataJanuary 6, 2026 | globenewswire.comAclarion (ACON) price target increased by 15.00% to 23.46December 7, 2025 | msn.comAclarion stock rises after feature in special pain issue of spine journalDecember 4, 2025 | au.investing.comAclarion shares move higher after Nociscan highlighted in spine surgery journalDecember 4, 2025 | msn.comAclarion announces publication of Nociscan article in pain issue of IJSSDecember 4, 2025 | msn.comAclarion, Inc. Stock (ACON) Opinions on Nociscan Technology PublicationDecember 4, 2025 | quiverquant.comQAclarion's Nociscan Featured in International Journal of Spine Surgery's Special Pain Issue, Highlighting Advances in Chronic Low Back Pain DiagnosisDecember 4, 2025 | quiverquant.comQAclarion Announces Publication of Nociscan Article in Special Pain Issue of the International Journal of Spine Surgery (IJSS)December 4, 2025 | globenewswire.comAclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S.December 2, 2025 | globenewswire.comAscendiant Capital Maintains Aclarion (ACON) Buy RecommendationNovember 21, 2025 | msn.comPositive Outlook on Aclarion, Inc. Driven by Revenue Growth and Strategic InvestmentsNovember 21, 2025 | tipranks.comAclarion Appoints Dan Isherwood as UK Commercial Director to Drive Growth of Nociscan in Musculoskeletal Imaging MarketNovember 5, 2025 | quiverquant.comQ Get Aclarion News Delivered to You Automatically Sign up to receive the latest news and ratings for ACON and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ACON Media Mentions By Week ACON Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ACON News Sentiment▼1.000.44▲Average Medical News Sentiment ACON News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ACON Articles This Week▼03▲ACON Articles Average Week Get the Latest News and Ratings for ACON and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Aclarion and its competitors. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies P3 Health Partners News Today Concord Medical Services News Today Basel Medical Group News Today Mangoceuticals News Today Marpai News Today Biorestorative Therapies News Today BioNexus Gene Lab News Today Agape ATP News Today NewGenIvf Group News Today IMAC News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ACON) was last updated on 5/23/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredThe AI stocks about to become worthless (and one that isn't)Louis Navellier - who manages $1.1 billion including $358 million in AI stocks - says a new AI computer being ...InvestorPlace | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aclarion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aclarion With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
